Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

PolyU Study Finds Orthokeratology Is an Effective Way for Retarding Myopia Progression
  • USA - English


News provided by

The Hong Kong Polytechnic University

May 13, 2014, 06:35 ET

Share this article

Share toX

Share this article

Share toX

Two schoolchildren, aged 11 and who had Ortho-K treatment, demonstrated how to wear Ortho-K lenses.
Two schoolchildren, aged 11 and who had Ortho-K treatment, demonstrated how to wear Ortho-K lenses.

(PRWEB) May 13, 2014 -- Professor Pauline Cho of School of Optometry from PolyU commented that prevalence of myopia (short-sightedness) was reaching epidemic proportions in the last decade. Severe myopia increased the risk of sight threatening diseases such as glaucoma, macular degeneration, and cataract. Thus, myopic progression is a major health issue which bothers parents.

Findings showed that the orthokeratology (Ortho-K) could slow down myopic progression by about 60% in school children.

Post this

To this end, research team of PolyU’s School of Optometry has conducted a number of researches on the effectiveness in controlling the progression of myopia in children. One of the studies completed in 2012 invited 78 children aged from 7 to 10 years old with myopia between 0.50D to 4.00D [1]. The results showed that myopic progression of those 37 children who received Ortho-K treatment were 43% slower compared with the rest of 41 children who wore spectacles. The effectiveness of the Ortho-K treatment was more significant in children aged between 7 to 8 years old. The study also found that 65% of children, whose myopia progressed annually by more than 1.00D, were wearing spectacles while only 20% of them had received Ortho-K treatment.

Another clinical study completed in 2013 was conducted among children aged from 8 to 11 years old with myopia more than 5.00D [2]. 12 of them received Ortho-K treatment while 16 of them wore spectacles. After two years, students who received Ortho-K had myopia increased by 0.13D whereas for those who wore spectacles, myopia increased by 1.00D. Myopia occurs when the eyeball is too long. The longer it is, the higher the degree of myopia. This study showed that Ortho-K slowed down eyeball elongation by 63%, meaning treatment is effective in alleviating myopic progression.

Another study completed in 2013 targeted at children with myopia and astigmatism [3]. 58 children from 6 to 12 years old with myopia between 0.50D to 5.00D and astigmatism between 1.25D to 3.50D were invited to participate in the study. The two-year clinical study reported that eyeball axial elongation of 35 children who received Ortho-K treatment was 0.31mm while 23 children who wore spectacles, the axial of eyeball elongated 0.64mm. This study indicated that Ortho-K treatment was an effective way to slow down the progression of myopia in moderate to high astigmatic children by 52%.

Ortho-K is a non-surgical treatment to correct vision. Myopes are required to wear specially designed rigid gas-permeable contact lenses at night. They can improve vision in the daytime without the need to wear spectacles or contact lenses. This brings convenience to daily life. Children aged from 6 to 11 years old can also benefit from Ortho-K treatment to retard myopic progression.

The Vice President (Internal) of The Hong Kong Academy of Orthokeratology, Ms Chan Ying-yee mentioned that Ortho-K lenses were tailor-made rigid contact lenses with high oxygen permeability that should only be prescribed by qualified optometrists after performing comprehensive eye examination. In general, about 60% of myopia could be reduced after 1 to 2 days of treatment and complete reduction of myopia could be achieved after 1 to 2 weeks of treatment. Ms Chan said that most optometrists recommend children aged 7 years old or above only to try Ortho-K treatment.

Since Ortho-K contact lenses are to be worn every night, children must be self-disciplined and strictly follow the instructions provided by optometrists. Therefore, parental support and monitoring are essential to ensure good compliance. Parents must assist their children in wearing and cleaning lenses, and arrange regular eye examination for them to ensure their eyes are in good condition. Hence, parents and children shall collaborate with optometrists to achieve the best outcome.

Remarks
[1] Retardation of Myopia in Orthokeratology (ROMIO) Study: A 2-Year Randomized Clinical Trial. Investigative Ophthalmology & Visual Science, October 2012, Vol. 53, No. 11

[2] High Myopia---Partial Reduction Ortho-k: A 2-Year Randomized Study. Optometry and Vision Science, Vol. 90, No. 6, June 2013

[3] Myopia Control Using Toric Orthokeratology (TO-SEE Study). Investigative Ophthalmology & Visual Science, October 2013, Vol. 54, No. 10

Agnes Kwan, The Hong Kong Polytechnic University, http://www.polyu.edu.hk, +852 27666374, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.